Mersana raises $27M to advance Fleximer antibody-drug conjugates
07:34 EDT 1 Aug 2012 | CentreWatch
Mersana Therapeutics, a Cambridge, Mass.-based biopharmaceutical company developing Fleximer antibody-drug conjugate (ADC) platform, has closed a $27 million Series A-1 financing led by new investor New Enterprise Associates (NEA).
Original Article: Mersana raises $27M to advance Fleximer antibody-drug conjugates
More From BioPortfolio on "Mersana raises $27M to advance Fleximer antibody-drug conjugates"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
